Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 9Other hematologic neoplasm 5Lymphoid 2Thoracic 1Sarcoma 1Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 325Lung Neoplasms 237Small Cell Lung Carcinoma 79Colorectal Neoplasms 30NSCLC 25Breast Neoplasms 22Neoplasms 16Adenocarcinoma of Lung 16Disease 15Neoplasm Metastasis 12Stomach Neoplasms 10Melanoma 10Ovarian Neoplasms 9Brain Neoplasms 9Uterine Cervical Neoplasms 8Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Pleural Effusion, Malignant 8Motor Activity 8Mesothelioma, Malignant 8Head and Neck Neoplasms 8Esophageal Neoplasms 7Endometrial Neoplasms 7Multiple Pulmonary Nodules 6Mesothelioma 6Carcinoma, Hepatocellular 6Thymoma 5Small Cell Lung Cancer Extensive Stage 5SCLC, Extensive Stage 5Recurrence 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Febrile Neutropenia × Thoracic × Clear all
NCT06143735 2023-11-22

A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
99 enrolled
Classical hematologyThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡